Zosuquidar
- Generic Name
- Zosuquidar
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31F2N3O2
- CAS Number
- 167354-41-8
- Unique Ingredient Identifier
- AB5K82X98Y
Overview
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Background
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Indication
Investigated for use/treatment in leukemia (myeloid) and myelodysplastic syndrome.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.